Search by Drug Name or NDC

NDC 00069-0235-30 Cibinqo 50 mg/1 Details

Cibinqo 50 mg/1

Cibinqo is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is ABROCITINIB.

MedlinePlus Drug Summary

Abrocitinib is used to treat moderate to severe eczema (atopic dermatitis; a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes) in adults who cannot use topical medications for their condition or whose eczema has not responded to topical medications. Abrocitinib is in a class of medications called Janus kinase (JAK) inhibitors. It works by decreasing the activity of the immune system.

Related Packages: 00069-0235-30
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Abrocitinib

Product Information

NDC	00069-0235
Product ID	0069-0235_9a98f605-9595-4c3e-a722-9cda77031e21
Associated GPIs	90272005000320
GCN Sequence Number	082989
GCN Sequence Number Description	abrocitinib TABLET 50 MG ORAL
HIC3	Z2Z
HIC3 Description	JANUS KINASE (JAK) INHIBITORS
GCN	51825
HICL Sequence Number	047767
HICL Sequence Number Description	ABROCITINIB
Brand/Generic	Brand
Proprietary Name	Cibinqo
Proprietary Name Suffix	n/a
Non-Proprietary Name	abrocitinib
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	TABLET, FILM COATED
Route	ORAL
Active Ingredient Strength	50
Active Ingredient Units	mg/1
Substance Name	ABROCITINIB
Labeler Name	Pfizer Laboratories Div Pfizer Inc
Pharmaceutical Class	Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]
DEA Schedule	n/a
Marketing Category	NDA
Application Number	NDA213871
Listing Certified Through	2024-12-31

Package

NDC 00069-0235-30 (00069023530)

Pricing Information	N/A
NDC Package Code	0069-0235-30
Billing NDC	00069023530
Package	30 TABLET, FILM COATED in 1 BOTTLE (0069-0235-30)
Marketing Start Date	2022-02-24
NDC Exclude Flag	N